Salute e Benessere

Laser Capture Microdissection Market Worth $306 million | MarketsandMarkets™

Browse in-depth TOC on "Laser Capture Microdissection Market" Browse in-depth TOC on "Laser Capture Microdissection Market" 139 - Tables 40 - Figures 193 - Pages Laser Capture Microdissection Market Scope: The consumables segment accounted for the largest share, by product in the laser capture microdissection market in 2023. By product, the laser capture microdissection market has been further categorized as instruments, consumables, software and services...
PR Newswire
14/03/2024

Inside information: Bioretec has been granted FDA Breakthrough Device…

Bioretec's biodegradable RemeOs™ Spinal Interbody Cage met the strict criteria set for entering the FDA's Breakthrough Device Designation program. FDA requires a breakthrough technology to provide more effective treatment for life-threatening or irreversibly debilitating conditions or diseases. In addition, breakthrough technology must either represent a completely new form of treatment or offer significant advantages over existing approved or cleared alternatives, including the potential to…
PR Newswire
14/03/2024

Electric Grill Market to Reach $7.72 Billion by 2031 Owing To Increasing in…

Market Dynamics: Market Dynamics : The Electric Grill Market is driven by the increasing preference for outdoor cooking among consumers, as it provides a convenient and hassle-free cooking experience. Additionally, the growing trend of healthy eating habits and the rising awareness about the harmful effects of traditional grilling methods have also propelled the demand for electric grills in the market. Electric Grill Market Report Coverage • Benefits such as low maintenance costs...
PR Newswire
14/03/2024

Combo IVD Market worth $920.9 Mn by 2031 - Exclusive Report by InsightAce…

Combo IVD Market Report Scope: Combo IVD Market Report Scope: Request for Sample Pages:https://www.insightaceanalytic.com/request-sample/2376 Combo In vitro diagnostic procedures involve the examination of a patient's blood or tissue samples. They help monitor the patient's vitals and are utilized for precise diagnostic testing of illnesses and other underlying conditions. Each patient's best course of treatment can be better determined with the help of these diagnostic tests...
PR Newswire
14/03/2024

Biotech's Role in Addressing the Pancreatic Cancer Emergency

There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13%. Among the therapy developers that have garnered accolades and support from PanCAN is Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), which late last year took home a US$5 millionTherapeutic Accelerator Award based on the promising results being delivered by its flagship asset, pelareorep. There is a point of optimism...
PR Newswire
14/03/2024

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate…

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2ACI-24.060 for Alzheimer's disease (AD) received FDA Fast Track designationACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partnerCash of CHF 103 million at year end, plus the...
Nasdaq GlobeNewswire
14/03/2024

Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal

Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc., said: "This is a monumental step forward for patient care in Portugal. With the approval of our first medical cannabis extract, we are proud to be at the forefront of medical cannabis research and accessibility and continue to demonstrate our commitment to providing innovative, safe, and effective therapeutic options to patients. We continue to pioneer the future of medical cannabis, furthering…
Nasdaq GlobeNewswire
14/03/2024

European Wellness and Sabah Government to Propel State into World-Class Medical…

Professor Mike Chan, along with his Sabahan wife Professor Dato' Sri Dr. Michelle Wong, underscores their vision to expand operations in Sabah, catering to the ASEAN and Brunei Darussalam-Indonesia-Malaysia-Philippines East ASEAN Growth Area (BIMP-Eaga) markets. With a strategic emphasis on medical wellness and education tourism, this partnership aims to harness Sabah's natural beauty, rich heritage, and European Wellness's expertise to create a holistic healthcare experience. ProfessorMike...
PR Newswire
14/03/2024

Casino Group: GPA capital increase and dilution of Casino stake

GPA capital increase and dilution of Casino stake Paris, 14 March 2024Following the communication made on December 11 th, 2023, Casino Group announces today the completion of Grupo Pão de Açucar ("GPA") primary offering with 220.000.000 new shares at 3,2 BRL per share, for a total placement amount of BRL 704 million.At the end of the transaction, the Casino Group's GPA capital stake will be 22.5% and will therefore no longer control the company. Casino Group will maintain 2 members...
Nasdaq GlobeNewswire
14/03/2024

Key protein linked to immune disorders

The researchers found that STAP-1 plays an important role in the activation of T cells, which are white blood cells that play a critical role in defending the body against infections and maintaining overall health. T cells are adept at recognizing foreign molecules that trigger an immune response (antigens) and mounting targeted responses to eliminate pathogens, such as bacteria and viruses. The researchers found that STAP-1 plays an important role in the activation of T cells, which are…
PR Newswire
14/03/2024

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio…

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity. Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by...
PR Newswire
14/03/2024

SRETT is expanding its Vestalis solution for digitising the patient care path

In 2024, SRETT is creating an offer based on Vestalis aimed at digitising every stage of the care path for people suffering from sleep apnoea or respiratory failure, for both clinical or administrative and logistical aspects. To do so, SRETT will make use of open-source business management software, while giving customers the option to interface Vestalis with their own ERP system. By 2025, they envisage adding new features and other therapeutic areas. In 2024, SRETT is creating an offer based...
PR Newswire
14/03/2024

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In…

Novo Holdings, through its Seed Investment team, has built a long-standing relationship with the Asgard team beginning with an incubation period focused on strategic and development counsel, guidance from Entrepreneurs-in-Residence and networking support. Novo Holdings also previously participated in Asgard's seed financing as a founding investor. Novo Holdings, through its Seed Investment team, has built a long-standing relationship with the Asgard team beginning with an incubation period...
PR Newswire
14/03/2024

Asgard Therapeutics announces €30 million Series A financing to advance its…

Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics, said: "Asgard's technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly inside the patient's body. We believe this breakthrough strategy will give rise to the next generation of cell therapies. This financing also follows a strong pre-clinical package providing PoC for AT-108. We would like to thank both new and existing investors…
PR Newswire
14/03/2024

Halton Healthcare selects Sectra's cloud SaaS to optimize enterprise imaging…

"This service will also enable us to explore additional technologies such as integrating AI-powered workflows and expanding into other enterprise imaging modalities in the future," continues Dr. Valadka. "We are excited to realize the positive impacts and advantages that this implementation will offer to our staff, patients, and community." "This service will also enable us to explore additional technologies such as integrating AI-powered workflows and expanding into…
PR Newswire
14/03/2024

Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement…

Novo Holdings co-led the Series A financing in 2019 when eneboparatide was still at preclinical stage, and continued to support the company through its follow-on Series B and Series C investments. This investment highlights Novo Holdings' evergreen structure and its ability to take a long-term view to advance science and medicine for the benefit of society, supporting early stage companies to advance programmes all the way through to late stage development. Novo Holdings co-led the Series A...
PR Newswire
14/03/2024

World Kidney Day 2024: Advancing equitable access to care and optimal medication…

On March 14, 2024, the World Kidney Day call to action is "Kidney Health for All: Advancing equitable access to care and optimal medication practice" to improve the quality of life and delay disease progression for people living with kidney disease. On March 14, 2024,the World Kidney Day call to action is " Kidney Health for All: Advancing equitable access to care and optimal medication practice " to improve the quality of life and delay disease progression for people living…
PR Newswire
14/03/2024

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March14, 2024(GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a...
Nasdaq GlobeNewswire
14/03/2024

Relation Therapeutics secures $35 million of new seed financing led by DCVC and…

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures,NVIDIA's venture armLondon, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million. This latest round was led by DCVC and co-led by NVIDIA's venture arm, NVentures, with participation from...
Nasdaq GlobeNewswire
14/03/2024

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

Hyloris Reports Full Year Results for 2023 & Provides Business OutlookTotal revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly fueled by the recent launch in the U.S. of Maxigesic® IV and Podofilox gel, the global roll out of Maxigesic IV® and commercial dealsIncreased operating R&D expenses while net operating cash outflow remained stable versus 2022Significant R&D progress including clinical and...
Nasdaq GlobeNewswire
14/03/2024

Addex to Present at the Bio-Europe Spring 2024 Conference

Geneva, Switzerland, March 14, 2024–Addex Therapeutics(SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at theBio-Europe Spring 2024conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event. In his presentation, Mr Dyer will provide a corporate update and discuss recent...
Nasdaq GlobeNewswire
14/03/2024

Pharming Group reports fourth quarter and full year 2023 financial results

Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 millionStrong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 millionOverall cash and marketable securities increased to US$215.0 million at the end of 2023 from ...
Nasdaq GlobeNewswire
14/03/2024

PanTera signs a second agreement for the supply of actinium-225

PanTera's continues to deploy its strategy to become a market leader into the production and distribution of Ac225 Mol, Belgium, March 14, 2024:PanTera, the Belgian radioisotope producer created as a joint venture by IBA and SCK CEN with the primary goal to secure large-scale production of actinium-225 ( 225 Ac), today announces the signing of a strategic supply contract with an undisclosed partner. This second supply agreement from PanTera underscores its commitment to enabling the...
Nasdaq GlobeNewswire
14/03/2024

Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in…

AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and olderThis follows the first commercial launch of AGAMREE in Germany in January 2024 by SantheraAGAMREE is the first DMD treatment approved across the U.S., EU and UKPratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne...
Nasdaq GlobeNewswire
14/03/2024
Altri  Comunicati